Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Recurrent Clostridium Difficile Infection With RBX7455

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria:~1. ≥ 18 years old.~2. Medical record documentation of recurrent CDI, defined as at least one recurrence after a primary episode and has completed at least two rounds of standard-of-care oral antibiotic therapy. Study subjects will have their diarrhea resolved, i.e., would be having less than 3 watery bowel movements at the time of study enrollment for 48 hours or more.~3. A positive stool test for the presence of C. difficile within 30 days prior to enrollment and standard C. difficile treatment.~4. Willing and able to swallow capsules.~5. Agrees to abstain from non-dietary probiotics for the duration of the study.~6. Agrees to abstain from vancomycin, metronidazole, fidaxomicin, rifaximin, nitazoxanide and IVIG for the duration of the study unless prescribed to treat recurrent CDI.~7. Agrees to stop proton pump inhibitors or H2 blocker medications.~8. Agrees to practice a form of effective contraception during study participation.~9. Has a negative urine pregnancy test at the time of enrollment (females of child-bearing potential only).~10. Willing and able to provide informed consent and HIPAA authorization.~11. Willing and able to complete the required Subject Diary.~12. Willing and able to meet all study requirements, including attending all assessment visits and phone calls.~Exclusion criteria:~1. A known history of continued CDI diarrhea, despite being on a course of antibiotics prescribed for CDI treatment.~2. Requires continuous antibiotic therapy for a condition other than CDI.~3. Previous fecal transplant.~4. Previous treatment with RBX2660.~5. Diagnosis of inflammatory bowel disease (IBD), e.g., ulcerative colitis, Crohn's disease, or microscopic colitis.~6. Diagnosis of irritable bowel syndrome (IBS) as determined by Rome III criteria.~7. History of chronic diarrhea.~8. History of celiac disease.~9. Disease symptoms caused by a confirmed intestinal pathogen other than C. difficile.~10. Unable to stop proton pump inhibitors or H2 blocker medications.~11. Colostomy.~12. Intra-abdominal surgery within the last 60 days.~13. Evidence of active, severe colitis.~14. History of short gut syndrome.~15. Requires the regular use of medications to manage bowel hypermotility.~16. Planned therapy in the next 3 months that may cause diarrhea (e.g., chemotherapy).~17. Planned surgery requiring perioperative antibiotics within 3 months of study enrollment.~18. Life expectancy of \< 6 months.~19. Compromised immune system (e.g., HIV infection; AIDS-defining diagnosis or CD4 \<200/mm3; inherited/primary immune disorders; immunodeficient or immunosuppressed due to a medical condition or medication; current or recent (\< 90 days) treatment with chemotherapy; or current or recent (\< 90 days) treatment with immunosuppressant medications.~20. Taking systemic steroids (≥ 20 mg a day or prednisone-equivalent) or is expected to be on steroids after enrollment through 8 weeks after completing the assigned study treatment.~21. An absolute neutrophil count of \<1000 cells/µL.~22. Known or suspected current (\< 90 days) illicit drug use. Note: marijuana use is allowed.~23. Pregnant, breastfeeding, or intends to become pregnant during study participation.~24. Participating in a clinical trial of another investigational product (drug, device or other) and has not completed the required follow-up period.~25. Subject, in the opinion of the investigator, for whatever reason, should be excluded from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- RBX7455 Group A (Type: ACTIVE_COMPARATOR): 4 days of 4 capsules twice daily RBX7455 for 10 subjects.
- RBX7455 Group B (Type: ACTIVE_COMPARATOR): 2 days of 4 capsules twice daily RBX7455 for 10 subjects.
- RBX7455 Group C (Type: ACTIVE_COMPARATOR): 2 days of 2 capsules twice daily RBX7455 for 10 subjects.
- RBX7455 Group D (Type: ACTIVE_COMPARATOR): 2 days of 1 capsule twice daily RBX7455 for 10 subjects.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete